题目内容
Kymriah (tisagenlecleucel, Novartis) is a CD29-directed chimeric antigen receptor (CAR) T-cell immunotherapy.
查看答案
搜索结果不匹配？点我反馈
更多问题
Each dose of Kymriah is a customized treatment created using patient's own B-cells, a type of white blood cell known as a lymphocyte.
The safety and efficacy of Kymriah were demonstrated in one multicenter clinical trial of 63 pediatric and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The overall remission rate within three months of treatment was 43%.
The FDA approved tisagenlecleucel with a Risk Evaluation and Mitigation Strategy (REMS) program, because of the associated risk for cytokine release syndrome (CRS) and neurologic adverse events with this immunotherapy.
The FDA required that clinicians who dispense tisagenlecleucel are specially certified on prescribing, dispensing, and administering this medication and on recognizing and managing CRS and the associated neurologic adverse reactions.
微信支付 
支付宝支付